Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247

Stock Information for Satellos Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Satellos Bioscience Inc.

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.